Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl

PL EN


Preferences help
enabled [disable] Abstract
Number of results

Journal

2010 | 5 | 6 | 704-711

Article title

Prevalence and recurrence rate of colonic lesions in acromegalic patients

Content

Title variants

Languages of publication

EN

Abstracts

EN
Acromegaly is associated with an increased prevalence of colonic polyps. The aim of this study was to evaluate the prevalence and recurrence rate of colonic polyps in acromegalic patients. Ninety-six acromegalic patients and 100 irritable bowel syndrome patients (IBS) were enrolled in the study. Twenty patients who were cured exclusively by surgery, and 20 patients that could not be hormonally controlled were re-examined colonoscopically after 36 months. Twenty-nine of 96 acromegalic patients (30.2%) had colonic polyps. In the IBS group, 10 (10.0%) had colonic polyps. The prevalence of colonic polyps was significantly higher in acromegaly. The group of acromegalic patients with and without polyps did not differ significantly with regard to plasma GH, IGF-I, fasting insulin levels and glycemic status. The presence of colonic polyps was correlated with increased patient age and male gender. We did not observe a difference in terms of polyp recurrence frequencies in the patients cured by surgery compared to uncontrolled patients. Acromegalic patients have a higher prevalence of colonic polyps than that of control subjects. We could not identify any factors that could predict polyps within the acromegalic patients - but age and male sex.

Keywords

EN

Publisher

Journal

Year

Volume

5

Issue

6

Pages

704-711

Physical description

Dates

published
1 - 12 - 2010
online
7 - 10 - 2010

Contributors

author
  • Endocrinology and Metabolism Clinic, Ministry Of Health, Ankara Numune Research and Training Hospital, 06100, Ankara, Turkey
  • Endocrinology and Metabolism Clinic, Ministry Of Health, Ankara Numune Research and Training Hospital, 06100, Ankara, Turkey
author
  • Endocrinology and Metabolism Clinic, Ministry Of Health, Ankara Numune Research and Training Hospital, 06100, Ankara, Turkey
author
  • Endocrinology and Metabolism Clinic, Ministry Of Health, Ankara Numune Research and Training Hospital, 06100, Ankara, Turkey
author
  • Endocrinology and Metabolism Clinic, Ministry Of Health, Ankara Numune Research and Training Hospital, 06100, Ankara, Turkey
author
  • Endocrinology and Metabolism Clinic, Ministry Of Health, Ankara Numune Research and Training Hospital, 06100, Ankara, Turkey
author
  • Gastroenterology Clinic, Ministry Of Health, Diskapi Yildirim Beyazit Research and Training Hospital, 06200, Ankara, Turkey
author
  • Department of Biochemistry, Ministry Of Health, Ankara Numune Research and Training Hospital, 06100, Ankara, Turkey
  • Gastroenterology Clinic, Ministry Of Health, Ankara Numune Research and Training Hospital, 06100, Ankara, Turkey
author
  • Endocrinology and Metabolism Clinic, Ministry Of Health, Ankara Numune Research and Training Hospital, 06100, Ankara, Turkey

References

  • [1] Koenuma M., Yamori T., Tsuruo T., Insulin and insulin-like growth factor 1 stimulate proliferation of metastatic variants of colon carcinoma 26, Jpn J Cancer Res., 1989, 80, 51–58
  • [2] Watkins LF., Lewis LR., Levine AE., Characterization of the synergistic effect of insulin and transferring and the regulation of their receptors on a human colon carcinoma cell line, Int J Cancer., 1990, 45, 372–375 http://dx.doi.org/10.1002/ijc.2910450227[Crossref]
  • [3] Bjork J., Nilsson J., Hultcrantz R., Johansson C., Growth-regulatory effects of sensory neuropeptides, epidermal growth factor, insulin, and somatostatin on the nontransformed intestinal epithelial cell line IEC-6 and the colon cancer cell line HT 29, Scand J Gastroenterol., 1993, 28, 879–884 http://dx.doi.org/10.3109/00365529309103129[Crossref]
  • [4] Hansen I., Tsalikian E., Beaufrere B., Gerich J., Haymond M., Rizza R., Insulin resistance in acromegaly: defects in both hepatic and extrahepatic insulin action, Am J Physiol., 1986, 250, E269–273
  • [5] McKeown-Eyssen G., Epidemiology of colorectal cancer revisited: are serum triglycerides and/or plasma glucose associated with risk?, Cancer Epidemiol Biomarkers Prev., 1994, 3, 687–695
  • [6] La Vecchia C., Negri E., Franceschi S., D’Avanzo B., Boyle P., A case-control study of diabetes mellitus and cancer risk, Br J Cancer., 1994, 70, 950–953 [Crossref]
  • [7] Le Marchand L., Wilkens LR., Kolonel LN., Hankin JH., Lyu LC., Associations of sedentary lifestyle, obesity, smoking, alcohol use, and diabetes with the risk of colorectal cancer, Cancer Res., 1997, 57, 4787–4794
  • [8] Sandhu MS., Luben R., Khaw KT., Self reported noninsulin dependent diabetes, family history, and risk of prevalent colorectal cancer: population based, cross sectional study, J Epidemiol Community Health., 2001, 55, 804–805 http://dx.doi.org/10.1136/jech.55.11.804[Crossref]
  • [9] Ron E., Gridley G., Hrubec Z., Page W., Arora S., Fraumeni JF Jr., Acromegaly and gastrointestinal cancer, Cancer., 1991, 68, 1673–1677 http://dx.doi.org/10.1002/1097-0142(19911015)68:8<1673::AID-CNCR2820680802>3.0.CO;2-0[Crossref]
  • [10] Pines A., Rozen P., Ron E., Gilat T., Gastrointestinal tumors in acromegalic patients, Am J Gastroenterol., 1985, 80, 266–269
  • [11] Baris D., Gridley G., Ron E., Weiderpass E., Mellemkjaer L., Ekbom A., et al., Acromegaly and cancer risk: a cohort study in Sweden and Denmark, Cancer Causes Control., 2002, 13, 395–400 http://dx.doi.org/10.1023/A:1015713732717[Crossref]
  • [12] Ladas SD., Thalassinos NC., Ioannides G., Raptis SA., Does acromegaly really predispose to an increased prevalence of gastrointestinal tumours?, Clin Endocrinol (Oxf)., 1994, 41, 597–601 http://dx.doi.org/10.1111/j.1365-2265.1994.tb01824.x[Crossref]
  • [13] Ortego J., Vega B., Sampedro J., Escalada J., Boixeda D., Varela C., Neoplastic colonic polyps in acromegaly, Horm Metab Res., 1994, 26, 609–610 http://dx.doi.org/10.1055/s-2007-1001769[Crossref]
  • [14] Renehan AG., Bhaskar P., Painter JE., O’Dwyer ST., Haboubi N., Varma J., et al., The prevalence and characteristics of colorectal neoplasia in acromegaly, J Clin Endocrinol Metab., 2000, 85, 3417–3424 http://dx.doi.org/10.1210/jc.85.9.3417[Crossref]
  • [15] Jenkins PJ., Besser M., Clinical perspective: acromegaly and cancer: a problem, J Clin Endocrinol Metab., 2001, 86, 2935–2941 http://dx.doi.org/10.1210/jc.86.7.2935[Crossref]
  • [16] Jenkins PJ., Fairclough PD., Colorectal neoplasia in acromegaly, Clin Endocrinol (Oxf)., 2001, 55, 727–729 http://dx.doi.org/10.1046/j.1365-2265.2001.01418.x[Crossref]
  • [17] Atkin WS., Risk of colorectal neoplasia in acromegaly: an independent view, Clin Endocrinol (Oxf)., 2001, 55, 723–725 http://dx.doi.org/10.1111/j.1365-2265.2001.01410.x[Crossref]
  • [18] Colao A., Pivonello R., Auriemma RS., Galdiero M., Ferone D., Minuto F., et al., The association of fasting insulin concentrations and colonic neoplasms in acromegaly: a colonoscopy-based study in 210 patients, J Clin Endocrinol Metab., 2007, 92, 3854–3860 http://dx.doi.org/10.1210/jc.2006-2551[Crossref][WoS]
  • [19] Kurimoto M., Fukuda I., Hizuka N., Takano K., The prevalence of benign and malignant tumors in patients with acromegaly at a single institute, Endocr J., 2008, 5, 67–71 http://dx.doi.org/10.1507/endocrj.K07E-010[WoS][Crossref]
  • [20] Levin B., Lieberman DA., McFarland B., Andrews KS., Brooks D., Bond J., et al., American Cancer Society Colorectal Cancer Advisory Group; US Multi-Society Task Force; American College of Radiology Colon Cancer Committee. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology., 2008, 134, 1570–1595 http://dx.doi.org/10.1053/j.gastro.2008.02.002[Crossref]
  • [21] Inoue M., Iwasaki M., Otani T., Sasazuki S., Noda M., Tsugane S., Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan, Arch Intern Med., 2006, 166, 1871–1877 http://dx.doi.org/10.1001/archinte.166.17.1871[Crossref]
  • [22] Ragozzino M., Melton LJ 3d., Chu CP., Palumbo PJ., Subsequent cancer risk in the incidence cohort of Rochester, Minnesota, residents with diabetes mellitus, J Chronic Dis., 1982, 35, 13–19 http://dx.doi.org/10.1016/0021-9681(82)90025-X
  • [23] La Vecchia C., Negri E., Decarli A., Franceschi S., Diabetes mellitus and colorectal cancer risk, Cancer Epidemiol Biomarkers Prev., 1997, 6, 1007–1010 [WoS]
  • [24] Hu FB., Manson JE., Liu S., Hunter D., Colditz GA., Michels KB., et al., Prospective study of adult onset diabetes mellitus (Type 2) and risk of colorectal cancer in women, J Natl Cancer Inst., 1999, 91, 542–547 http://dx.doi.org/10.1093/jnci/91.6.542[Crossref]
  • [25] Jee SH., Ohrr H., Sull JW., Yun JE., Ji M., Samet JM., Fasting serum glucose level and cancer risk in Korean men and women, JAMA., 2005, 293, 194–202 http://dx.doi.org/10.1001/jama.293.2.194[Crossref]
  • [26] Yang YX., Hennessy S., Lewis JD., Type 2 diabetes mellitus and the risk of colorectal cancer, Clin Gastroenterol Hepatol., 2005, 3, 587–594 http://dx.doi.org/10.1016/S1542-3565(05)00152-7[Crossref]
  • [27] Nilsen TI., Vatten LJ., Prospective study of colorectal cancer risk and physical activity, diabetes, blood glucose and BMI. Exploring the hyperinsulinaemia hypothesis, Br J Cancer., 2001, 84, 417–422 http://dx.doi.org/10.1054/bjoc.2000.1582[Crossref]
  • [28] Larsson SC., Orsini N., Wolk A., Diabetes mellitus and risk of colorectal cancer: a meta-analysis, J Natl Cancer Inst., 2005, 97, 1679–1687 http://dx.doi.org/10.1093/jnci/dji375[Crossref]
  • [29] MacDonald RS., Thornton WH Jr., Bean TL., Insulin and IGE-1 receptors in a human intestinal adenocarcinoma cell line (CACO-2): regulation of Na+ glucose transport across the brush border, J Recept Res., 1993, 13, 1093–1113
  • [30] Guo YS., Narayan S., Yallampalli C., Singh P., Characterization of insulin like growth factor I receptors in human colon cancer, Gastroenterology., 1992, 102, 1101–1108
  • [31] Warren RS., Yuan H., Matli MR., Ferrara N., Donner DB., Induction of vascular endothelial growth factor by insulin-like growth factor 1 in colorectal carcinoma, J Biol Chem., 1996, 271, 29483–29488 http://dx.doi.org/10.1074/jbc.271.46.29483[Crossref]
  • [32] Giovannucci E., Pollak MN., Platz EA., Willett WC., Stampfer MJ., Majeed N., et al., A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women, Cancer Epidemiol Biomarkers Prev., 2000, 9, 345–349
  • [33] Ma J., Pollak MN., Giovannucci E., Chan JM., Tao Y., Hennekens CH., et al., Prospective study of colorectal cancer risk in men and plasma levels of insulin like growth factor (IGF)-I and IGF-binding protein-3, J Natl Cancer Inst., 1999, 91, 620–625 http://dx.doi.org/10.1093/jnci/91.7.620[Crossref]
  • [34] Juul A., Pedersen SA., Sørensen S., Winkler K., Jørgensen JO., Christiansen JS., et al., Growth hormone (GH) treatment increases serum insulin-like growth factor binding protein-3, bone isoenzyme alkaline phosphatase and forearm bone mineral content in young adults with GH deficiency of childhood onset, Eur J Endocrinol., 1994, 131, 41–49 http://dx.doi.org/10.1530/eje.0.1310041[Crossref]
  • [35] Ghigo E., Aimaretti G., Maccario M., Fanciulli G., Arvat E., Minuto F., et al., Doseresponse study of GH effects on circulating IGF-I and IGFBP-3 levels in healthy young men and women, Am J Physiol., 1999, 276, E1009–1013
  • [36] Giovannucci E., Pollak M., Risk of cancer after growth hormone treatment, Lancet., 2002, 360, 268–269 http://dx.doi.org/10.1016/S0140-6736(02)09561-2[Crossref]
  • [37] Cohen P., Fielder PJ., Hasegawa Y., Frisch H., Giudice LC., Rosenfeld RG., Clinical aspects of insulin-like growth factor binding proteins, Acta Endocrinol (Copenh)., 1991, 124, 74–85
  • [38] Nam SY., Lee EJ., Kim KR., Cha BS., Song YD., Lim SK., et al., Effect of obesity on total and free insulin-like growth factor (IGF)-I and their relationship to IGFbinding protein (BP)-1, IGFBP-2, IGFBP-3, insulin, and growth hormone, Int J Obes Relat Metab Disord., 1997, 21, 355–359 http://dx.doi.org/10.1038/sj.ijo.0800412[Crossref]
  • [39] Orme SM., McNally RJ., Cartwright RA., Belchetz PE., Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group, J Clin Endocrinol Metab., 1998, 83, 2730–2734 http://dx.doi.org/10.1210/jc.83.8.2730[Crossref]
  • [40] Barzilay J., Heatley GJ., Cushing GW., Benign and malignant tumors in patients with acromegaly, Arch Intern Med., 1991, 151, 1629–1632 http://dx.doi.org/10.1001/archinte.151.8.1629[Crossref]
  • [41] Colao A., Balzano A., Ferone D., Panza N., Grande G., Marzullo P., et al., Increased prevalence of colonic polyps and altered lymphocyte subset pattern in the colonic lamina propria in acromegaly, Clin Endocrinol (Oxf)., 1997, 47, 23–28 http://dx.doi.org/10.1046/j.1365-2265.1997.00253.x[Crossref]
  • [42] Delhougne B., Deneux C., Abs R., Chanson P., Fierens H., Laurent-Puig P., et al., The prevalence of colonic polyps in acromegaly: a colonoscopic and pathological study in 103 patients, J Clin Endocrinol Metab., 1995, 80, 3223–3226 http://dx.doi.org/10.1210/jc.80.11.3223[Crossref]
  • [43] Pawlikowski M., Lachowicz L., Kunert-Radek J., Winczyk K., Janiszewska G., Szkudlarek J., Differential effects of somatostatin and its analog on protein tyrosine kinases activity in the rat pituitary and the murine colonic tumors, Biochem Biophys Res Commun., 1998, 246, 375–377 http://dx.doi.org/10.1006/bbrc.1998.8624[Crossref]

Document Type

Publication order reference

Identifiers

YADDA identifier

bwmeta1.element.-psjd-doi-10_2478_s11536-010-0041-6
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.